A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Inclusion Criteria: * Written informed consent before any study-related procedure is performed. * Body mass index (BMI) between 18 and 32 kg/m2, inclusive. * No clinically significant abnormalities based on medical history, laboratory assessments, vital sign, 12-lead electrocardiogram (ECG) results, and physical examination. * Subjects willing and able to follow a prescribed diet. * Subjects have not consumed nicotine or nicotine-containing products for at least 6 months before Screening. * Subjects are nonpregnant and nonlactating, surgically sterile, postmenopausal, abstinent, or the subject or partner is willing to use a reliable method of contraception during the study and for 5 months after mipomersen dosing. Exclusion Criteria: * Poor metabolizer of warfarin as determined by CYP2C9 genotype testing. * Clinically significant PT, aPTT, INR, protein C, protein S, or platelet count results or hematuria. * Abnormal prolongation of skin bleeding time or a personal or family history of coagulation or bleeding disorders, vascular malformations including aneurysms, or venous thromboembolism. * Active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease. * Active malignancy of any type other than nonmelanomatous skin malignancies. * Use of any prescribed or over-the-counter concomitant medications within 14 days before the first dose of investigational product without approval of the Investigator and Sponsor. * Positive test result for drugs of abuse, alcohol, or cotinine or history of alcohol abuse or drug addiction. * Positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or HIV.